Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor–deficient mice

T Cyrus, S Sung, L Zhao, CD Funk, S Tang, D Praticò - Circulation, 2002 - Am Heart Assoc
T Cyrus, S Sung, L Zhao, CD Funk, S Tang, D Praticò
Circulation, 2002Am Heart Assoc
Background—Atherosclerosis is a complex vascular inflammatory disease. Low-dose
aspirin is a mainstay in the prevention of vascular complications of atherosclerosis. We
wished to determine the effect of low-dose aspirin on vascular inflammation, plaque
composition, and atherogenesis in LDL receptor–deficient mice fed a high fat diet. Methods
and Results—In LDL receptor–deficient mice fed a high fat diet compared with control mice,
low-dose aspirin induced a significant decrease in circulating levels and vascular formation …
Background— Atherosclerosis is a complex vascular inflammatory disease. Low-dose aspirin is a mainstay in the prevention of vascular complications of atherosclerosis. We wished to determine the effect of low-dose aspirin on vascular inflammation, plaque composition, and atherogenesis in LDL receptor–deficient mice fed a high fat diet.
Methods and Results— In LDL receptor–deficient mice fed a high fat diet compared with control mice, low-dose aspirin induced a significant decrease in circulating levels and vascular formation of soluble intercellular molecule-1, monocyte chemoattractant protein-1, tumor necrosis factor-α, interleukin-12p 40, without affecting lipid levels. This was associated with significant reduction of the nuclear factor κB activity in the aorta. Low-dose aspirin also significantly reduced the extent of atherosclerosis. Finally, aortic vascular lesions of the aspirin-treated animals showed 57% reduction (P<0.05) in the amount of macrophage cells, 77% increase in smooth muscle cells (P<0.05), and 23% increase in collagen (P<0.05).
Conclusions— Our results suggest that in murine atherosclerosis, low-dose aspirin suppresses vascular inflammation and increases the stability of atherosclerotic plaques, both of which, together with its antiplatelet activity, contribute to its antiatherogenic effect. We conclude that low-dose aspirin might be rationally evaluated in the progression and evolution of human atherosclerotic plaque.
Am Heart Assoc